NYMOX PHARMACEUTICAL CORPORATION Amortisation Expense
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) reported Amortisation Expense of $0 for the 12-month period ending 2024-12-31, per its 20-F filed 2025-06-03.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:AmortisationExpense · last filed 2025-06-03
- NYMOX PHARMACEUTICAL CORPORATION amortisation expense for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION amortisation expense for the quarter ending 2023-12-31 was $8.00K, a 86.21% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION amortisation expense for the quarter ending 2023-09-30 was $38.00K, a 34.48% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION amortisation expense for the quarter ending 2023-06-30 was $56.00K, a 6.67% decline year-over-year.
| Period end | Amortisation Expense 3 month | Amortisation Expense 6 month | Amortisation Expense 9 month | Amortisation Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2025-06-03 | $0.00 20-F · filed 2025-06-03 | ||
| 2024-09-30 | $0.00 6-K · filed 2025-01-02 | |||
| 2023-12-31 | $8.00K derived: 20-F 12 month − 6-K 9 month · filed 2025-06-03 | $46.00K derived: sum of 2 quarters · filed 2025-06-03 | $102.00K derived: sum of 3 quarters · filed 2025-06-03 | $158.00K 20-F · filed 2025-06-03 |
| 2023-09-30 | $38.00K derived: 6-K 9 month − 6-K 6 month · filed 2025-01-02 | $94.00K derived: sum of 2 quarters · filed 2025-01-02 | $150.00K 6-K · filed 2025-01-02 | $208.00K derived: sum of 4 quarters · filed 2025-06-03 |
| 2023-06-30 | $56.00K derived: 6-K 6 month − 6-K 3 month · filed 2023-08-14 | $112.00K 6-K · filed 2023-08-14 | $170.00K derived: sum of 3 quarters · filed 2025-06-03 | $228.00K derived: sum of 4 quarters · filed 2025-06-03 |
| 2023-03-31 | $56.00K 6-K · filed 2023-05-12 | $114.00K derived: sum of 2 quarters · filed 2025-06-03 | $172.00K derived: sum of 3 quarters · filed 2025-06-03 | $232.00K derived: sum of 4 quarters · filed 2025-06-03 |
| 2022-12-31 | $58.00K derived: 20-F 12 month − 6-K 9 month · filed 2025-06-03 | $116.00K derived: sum of 2 quarters · filed 2025-06-03 | $176.00K derived: sum of 3 quarters · filed 2025-06-03 | $237.00K 20-F · filed 2025-06-03 |
| 2022-09-30 | $58.00K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-15 | $118.00K derived: sum of 2 quarters · filed 2023-11-15 | $179.00K 6-K · filed 2023-11-15 | $240.00K derived: sum of 4 quarters · filed 2024-08-29 |
| 2022-06-30 | $60.00K derived: 6-K 6 month − 6-K 3 month · filed 2023-08-14 | $121.00K 6-K · filed 2023-08-14 | $182.00K derived: sum of 3 quarters · filed 2024-08-29 | $242.00K derived: sum of 4 quarters · filed 2024-08-29 |
| 2022-03-31 | $61.00K 6-K · filed 2023-05-12 | $122.00K derived: sum of 2 quarters · filed 2024-08-29 | $182.00K derived: sum of 3 quarters · filed 2024-08-29 | |
| 2021-12-31 | $61.00K derived: 20-F 12 month − 6-K/A 9 month · filed 2024-08-29 | $121.00K derived: sum of 2 quarters · filed 2024-08-29 | $242.00K 20-F · filed 2024-08-29 | |
| 2021-09-30 | $60.00K derived: 6-K/A 9 month − 6-K 6 month · filed 2022-11-16 | $181.00K 6-K/A · filed 2022-11-16 | ||
| 2021-06-30 | $121.00K 6-K · filed 2022-08-15 | |||
| 2020-12-31 | $258.00K 20-F · filed 2023-05-02 |